Find verified Remimazolam besylate API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Remimazolam besylate for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Remimazolam besylate API.
Alternate Names: Remimazolam Benzenesulfonate, Byfavo, anerem
CAS No: 1001415-66-2
PubChem CID: 23658607
Mol Formula: C27H25BrN4O5S
Mol Weight: 597.5 g/mol
IUPAC Name: benzenesulfonic acid;methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate
API Description: Remimazolam Besylate is the besylate ester form of remimazolam, a short-acting benzodiazepine derivative that is structurally related to midazolam, with sedative-hypnotic activity. Upon administration, remimazolam targets and binds to a specific site on the gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Remimazolam Besylate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sedation and has 1 investigational indication. This drug has a black box warning from the FDA.
